Letting the right one in: evaluating the generalisability of clinical trials
![Shrimanker R, Beasley R, Kearns C. Letting the right one in: evaluating the generalisability of clinical trials. Eur Respir J 2018; 52: 1802218 [https://doi.org/10.1183/13993003.02218- 2018].](https://images.squarespace-cdn.com/content/v1/5e9e7873f15ec443bd66cd3c/1589772475818-84CU9AMEMLCOR8CIEUPS/ERJ-diagram-Diagnostic-labelling-approach-in-targeted-treatment-research-by-Dr-CIlein-Kearns-v02-1024px.jpg)
Shrimanker R, Beasley R, Kearns C. Letting the right one in: evaluating the generalisability of clinical trials. Eur Respir J 2018; 52: 1802218 [https://doi.org/10.1183/13993003.02218- 2018].
“Diagnostic labelling” harms targeted therapy research in airways disease. We make a call to adopt the “treatable trait” approach with our latest publication in the European Respiratory Journal: http://erj.ersjournals.com/content/52/6/1802218
